Denali Therapeutics Inc. (DNLI) Investor Relations Documents

Denali Therapeutics Inc. (DNLI) investor relations documents from the company's IR site: 1 presentation, 14 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

Denali Therapeutics Q2 Earnings Presentation — Denali Therapeutics 2Q 2026 financial results report $3.6 million in net product revenue from the commercial launch of AVLAYAH for Hunter syndrome.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releasePDF Version
2026-08-06Press releaseDenali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
2026-08-06Earnings deckDenali Therapeutics Q2 Earnings Presentation
2026-07-27Press releasePDF Version
2026-07-27Press releaseDenali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
2026-07-09Press releaseDenali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and
2026-06-18Press releaseDenali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
2026-05-21Press releaseBiogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Dise
2026-05-07Press releaseDenali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
2026-04-03Press releaseDenali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Deme
2026-03-25Press releaseDenali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (M
2026-02-26Press releaseDenali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-02-02Press releaseDenali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSym
2026-01-29Press releaseDenali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Sy
2026-01-06Press releaseDenali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tivideno

DNLI overview · DNLI earnings · DNLI financials · DNLI KPIs · DNLI ownership · DNLI peers · DNLI filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.